Peter Maccallum Cancer Centre, Australia

This early-phase study tests a new treatment for people with a type of multiple myeloma that has returned or not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goals ar…

This study looks at whether adding precise radiation (SABR) to the current hormone therapy and CDK4/6 inhibitor can delay the need to change cancer drugs in people with ER-positive, HER2-negative advanced breast cancer that has started to grow in a few spots. About 74 participant…

This study tests a new radioactive drug, Lu-177 FAP-2286, in 20 adults with cancer of unknown primary (CUP) that has worsened after standard chemotherapy. The drug targets a protein on cancer cells to deliver radiation directly to tumors. The main goal is to see if the treatment …

This study looks at how chemotherapy combined with immunotherapy affects the ovaries and fertility in women with early-stage triple-negative breast cancer. Researchers will track hormone levels, menstrual patterns, and ovarian function for up to two years after treatment. No new …